Stock Ratings | Susquehanna raised its price target for Micron (MU) to $1,750; Rodman & Renshaw initiated coverage on Bolt (BOLT) with a price target of $22, representing a potential upside of 319.05%.

Aclarion
Micron Technology
Dell Technologies
Bolt Biotherapeutics
Rapid Micro

Aclarion

ACON

0.00

Micron Technology

MU

0.00

Dell Technologies

DELL

0.00

Bolt Biotherapeutics

BOLT

0.00

Rapid Micro

RPID

0.00

The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Ascendiant Capital: Maintaining a "buy" rating on Aclarion ( Aclarion, Inc.(ACON.US) ), while raising the price target from $7 to $7.5.

Susquehanna: Maintaining a "positive" rating on Micron Technology Micron Technology, Inc.(MU.US) stock, while raising the price target from $600 to $1,750.

Susquehanna: Upgrades Dell Dell Technologies, Inc. Class C(DELL.US) ) stock rating to "positive," raising price target from $138 to $700.

Rodman & Renshaw: Initial rating for Bolt Biotherapeutics ( Bolt Biotherapeutics, Inc.(BOLT.US) ) at "Buy", with a target price of $22.

Keybanc: Maintaining an "overweight" rating on Rapid Micro Biosystems ( Rapid Micro Biosystems, Inc. Class A(RPID.US) ), while lowering the price target from $8 to $5.

The symbol Classification Target price Current price Percentage of potential increase/decrease (Classification) Agency
Aclarion, Inc.(ACON.US) to lift $7.5 $3.28 128.66% Ascendiant Capital
Micron Technology, Inc.(MU.US) to lift $1750.0 $971.0 80.23% Susquehanna
Dell Technologies, Inc. Class C(DELL.US) to lift $700.0 $420.91 66.31% Susquehanna
Ambarella, Inc.(AMBA.US) to lift $120.0 $72.18 66.25% Rosenblatt
Elastic N.V.(ESTC.US) to lift $104.0 $64.7 60.74% Citigroup
Bolt Biotherapeutics, Inc.(BOLT.US) Initial classification $22.0 $5.25 319.05% Rodman & Renshaw
Rapid Micro Biosystems, Inc. Class A(RPID.US) cut $5.0 $2.01 148.76% Keybanc
American Eagle Outfitters, Inc.(AEO.US) cut $31.0 $15.8 96.2% UBS
Gap, Inc.(GAP.US) cut $40.0 $21.15 89.13% UBS
Braze(BRZE.US) cut $48.0 $25.63 87.28% Citigroup

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Truist Securities: Maintaining a "buy" rating on Amazon ( Amazon.com, Inc.(AMZN.US) ) stock, while raising the price target from $310 to $320.

Truist Securities: Maintaining a "Hold" rating on Costco Costco Wholesale(COST.US) ) stock, while raising the price target from $977 to $1011.

B of A Securities: Maintaining a "buy" rating on Costco Costco Wholesale(COST.US) stock, while raising the price target from $1185 to $1200.

Jefferies: Maintaining a "buy" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) , raising the price target from $500 to $775

RBC Capital: Maintaining Datadog's ( Datadog(DDOG.US) ) rating at "Outperforming the Market," while raising its price target from $219 to $250.

B of A Securities: Maintaining a "buy" rating on Dell ( Dell Technologies, Inc. Class C(DELL.US) ) stock, while raising the price target from $280 to $500.

JP Morgan: Maintaining Dell's ( Dell Technologies, Inc. Class C(DELL.US) ) rating at "overweight", while raising the price target from $280 to $500.

Scotiabank: Maintaining MongoDB's ( MongoDB, Inc. Class A(MDB.US) ) rating at "Outperforming the Market", while raising the price target from $310 to $395.

Wedbush: Maintaining MongoDB's ( MongoDB, Inc. Class A(MDB.US) ) rating at "Outperforming the Market," while raising the price target from $380 to $390.

Susquehanna: Maintaining a "positive" rating on Micron Technology Micron Technology, Inc.(MU.US) stock, while raising the price target from $600 to $1,750.

Morgan Stanley: Maintaining Okta's Okta(OKTA.US) rating at "overweight", while raising the price target from $101 to $115.

Needham: Maintaining a "buy" rating on Okta Okta(OKTA.US) ) stock, while raising the price target from $90 to $120.

Susquehanna: Maintaining a "positive" rating on SanDisk stock ( Sandisk Corporation(SNDK.US) ), while raising the price target from $20 to $32.5.

HSBC: Upgrades Snowflake ( Snowflake(SNOW.US) ) stock rating to "buy", raising price target from $176 to $289.

Citigroup: Maintaining a "buy" rating on Snowflake Snowflake(SNOW.US) , while raising the price target from $260 to $320.

First Coverage

Rodman & Renshaw: Initial rating for Bolt Biotherapeutics ( Bolt Biotherapeutics, Inc.(BOLT.US) ) at "Buy", with a target price of $22.

RBC Capital: Initial rating for Black Stone Minerals ( Black Stone Minerals LP(BSM.US) ) at "sector-matched", with a target price of $16.

Canaccord Genuity: Initial rating for Claritev Claritev(CTEV.US) ) stock at "Buy", with a target price of $32.

Citigroup: Initial rating for DouYu ( DouYu International Holdings Limited(DOYU.US) ) stock at "neutral", with a target price of $5.2.

reduction

Jefferies: Maintain the Elastic Elastic N.V.(ESTC.US) rating at "Buy", while lowering the target price from $95 to $75.

Barclays: Maintaining Li Auto's LI Auto(LI.US) ) rating at "market-weighted", while lowering the target price from $18 to $14.

Truist Securities: Maintaining its rating on Southern ( Southern Company(SO.US) ) at "Hold", while lowering its price target from $103 to $100.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.